Page last updated: 2024-08-23

daunorubicin and pi103

daunorubicin has been researched along with pi103 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Y; Ding, Q; Gu, R; Liang, J; Zhang, X	1

Other Studies

1 other study(ies) available for daunorubicin and pi103

Article	Year
PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Daunorubicin; Female; Flow Cytometry; Furans; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Pyridines; Pyrimidines; Signal Transduction; Young Adult	2013

Article

Year

PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.

Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Daunorubicin; Female; Flow Cytometry; Furans; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Pyridines; Pyrimidines; Signal Transduction; Young Adult

2013